Elranatamab 是一种抗 CD3E/TNFRSF17 的人源 IgG2κ 单克隆抗体。Elranatamab 的同型对照产品：Human IgG2 kappa, Isotype Control。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 145.21 kDa. The mass spectrum exhibits two peaks, suggesting the possible presence of a homodimer.

Anti-BCMA & CD3 Reference Antibody (Elranatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 99.34%, determined by SEC-HPLC.

Elranatamab-Bcmm bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Elranatamab-Bcmm bound to huBCMA-ECD-His , and the EC50 was 0.055 nM.

Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and the EC50 was 1.263 nM.

Elranatamab-Bcmm bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huCD3e-jurkat cells, and the EC50 was 64.990 nM.

Co-incubation of Elranatamab-Bcmm with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Elranatamab-Bcmm was able to activate the NF-AT signaling pathway, and the EC50 was 0.081 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.